“…The availability of serelaxin has permitted the study of relaxin-2’s effects in cardiovascular, renal, hepatic, and brain tissues, as well as its evaluation in several randomized placebo-controlled clinical trials [ 13 , 14 ]. To date, the pharmacology and specific mechanisms of the systemic action of treatment with serelaxin have been studied in more than 15 human clinical trials, including in healthy subjects [ 9 , 15 , 16 ] and in pregnancy [ 17 , 18 ], preeclampsia [ 19 ] (clinicaltrials.gov identifiers NCT00333307 and NCT01566630), acute and chronic heart failure (HF) [ 20 , 21 , 22 , 23 , 24 , 25 , 26 ], systemic sclerosis [ 27 , 28 , 29 ], renal and hepatic impairment [ 30 , 31 ], and cirrhosis [ 32 ].…”